Recombinant Human GSK-3 beta His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11739-KS

Catalog #
Availability
Size / Price
Qty
11739-KS-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P49841.2

Conjugate

Unconjugated

Applications

Enzyme Activity

View all GSK-3 beta Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human GSK-3 beta protein
Met 6-His tag Sumo-tag
(mutated, uncleavable)		 3c Protease site Human GSK-3 beta
(Ser2-Thr420)
Accession # P49841.2

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Protein identity confirmed by mass spectrometry

Predicted Molecular Mass

60 kDa

SDS-PAGE

55-64 kDa, under reducing conditions

Activity

Measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a peptide substrate.

The specific activity is >200 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human GSK-3 beta His-tag Protein, CF

Recombinant Human GSK-3 beta His-tag Enzyme Activity.

Recombinant Human GSK-3 beta His-tag (Catalog # 11739-KS) is measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a peptide substrate.

Recombinant Human GSK-3 beta His-tag SDS-PAGE.

2 μg/lane of Recombinant Human GSK-3 beta His-tag (Catalog # 11739-KS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-64 kDa, under reducing conditions.

Formulation, Preparation and Storage

11739-KS
Formulation Supplied as a 0.2 μm filtered solution in MES, NaCl, Glycerol and DTT.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: GSK-3 beta

Glycogen synthase kinase-3 beta (GSK3B) is a ubiquitously expressed, highly conserved serine/threonine kinase (1-3) with key roles in the transduction of regulatory and proliferative signals at the cell membrane. GSK3B is one of two mammalian isoforms of GSK that are constitutively active and have high homology with a kinase domain and an N-terminal phosphorylation site that auto-inhibits its activity by competing with a binding site for preferred pre-phosphorylated substrates (1, 2, 4). The isoforms differ in their sequence similarity at both the N- and C-termini. The GSK3 alpha isoform is primarily cytosolic and has a glycine-rich N-terminal region that excludes it from the nucleus, whereas GSK3B can be found in the nucleus. The different localization differentiates GSK3B biological activity supported by the fact that the GSK3B knockout is embryonically lethal while GSK3 alpha expression is unable to compensate (3). GSK3 has been confirmed to have a diverse and broad range of substrates within multiple cell signaling pathways to regulate glucose metabolism, insulin activity, and energy homeostasis and plays a role in a wide range of cellular processes, such as cell proliferation, differentiation, apoptosis, the cell cycle, the immune response, and organ development (3, 5-6). GSK3B is thus implicated in multiple diseases such as cancer (2, 7) neurodegenerative diseases such as Alzheimer's, bipolar disorder (BPD), psychiatric disorders, Parkinson's, aging (8, 9), inflammatory conditions, and metabolic disorders such as diabetes, cardiovascular disease, and atherosclerosis (2-3, 7-11). There is interest in development of GSK3 inhibitors as a therapeutic target to prevent their ability to phosphorylate their substrates and prevent downstream signaling pathways; clinical trials targeting GSK3 inhibition have been primarily focused on cancers and neurodegenerative and neurological diseases (2-3, 9). 

References

  1. Dajani, R. et al. (2001) Cell 105:721.
  2. Mancinelli, R. et al. (2017) Oxidative Med. Cell. Longev. 2017:4629495.
  3. Wang, L. et al. (2022) Med. Res. Rev. 42:946.  
  4. Cross, D.A.E. et al. (1995) Nature 378:785.
  5. Grimes C.A. and R.S. Jope (2001) Prog. Neurobiol. 65:391.
  6. Doble, B.W. and J.R. Woodgett (2003) J. Cell Sci. 116:1175.
  7. Lin, J. et al. (2020) Biochem. Biophys. Acta 1867:118659.
  8. Gianferrara, T. et al. (2022) Curr. Med. Chem. 29:4631.
  9. Arciniegas Ruiz, S.M.A. and H. Eldar-Finkelman (2022) Front. Mol. Neurosci 14:792364.
  10. Sharma, A.K. et al. (2020) Drug Discov. Today 25:633.
  11. Liang, L. et al. (2024) FASEB J. 38:e23458.

Long Name

Glycogen Synthase Kinase 3 beta

Alternate Names

GSK3 beta, GSK3B

Entrez Gene IDs

2932 (Human); 56637 (Mouse); 84027 (Rat)

Gene Symbol

GSK3B

UniProt

P49841.2

Additional GSK-3 beta Products

Product Documents for Recombinant Human GSK-3 beta His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human GSK-3 beta His-tag Protein, CF

For research use only

Privacy Policy
Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.